Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alfasigma S.p.A.
BioCentury | Oct 17, 2024
Deals
More, faster deals, but smaller deals — Lazard co-heads of biopharma on this year’s M&A
Michael Kingston and Dale Raine on the capital markets and global deal-making landscape
BioCentury | Sep 12, 2024
Management Tracks
Ovid promotes Alexander to COO
Plus: Tyra hires Warner as CMO and updates from Senisca, Closed Loop, NanoSyrinx and more
BioCentury | Sep 6, 2024
Data Byte
Advisory committee meetings on FDA’s September docket
Up for discussion are a new antibiotic, Ocaliva’s conversion to full approval, and whether to require PD-L1 as biomarker in certain solid tumors
BioCentury | Feb 12, 2024
Deals
Completing long comeback, liver play CymaBay agrees to $4.3B Gilead takeout
Gilead adds seladelpar, a PBC candidate now under priority review, to liver disease arsenal
BioCentury | Jan 23, 2024
Finance
2024 Buyside View, plus Arnold Ventures’ impact: a BioCentury podcast
Market-creating catalysts. Biopharma’s most effective critic. Plus Gilead data and expected IPOs
BioCentury | Jan 20, 2024
Finance
Buysiders are all about market-creating catalysts in 2024
BioCentury’s 32nd Buyside View finds MASH, obesity and pain are among the year’s most closely-watched categories
BioCentury | Oct 31, 2023
Deals
Oct. 31 Quick Takes: Lilly buying Beam’s opt-in rights for Verve base editing programs
Plus: GSK buys Janssen’s rights to Arrowhead HBV product and more from Galapagos, Sarepta, Amgen, LianBio and X4
BioCentury | Sep 26, 2023
Data Byte
Intercept’s highs and lows on the way to M&A outcome
After pair of FDA setbacks in NASH, Italian pharma Alfasigma to acquire liver disease company nearly a decade after stock peaked
Items per page:
1 - 9 of 9